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PreviewsIn combination, the findings by Chauv-
ette et al. (2012) and Grosmark et al.
(2012) do not question the concept of
global synaptic downscaling during sleep
but instead suggest that processes during
REM sleep should be taken into consider-
ation. Beyond this, Grosmark et al.’s find-
ings offer an interesting link between
global processes of downscaling and the
consolidation of specific memories in
local networks, because they analyze
firing occurring in the presence of hippo-
campal ripples, which regularly accom-
pany the neuronal replay of newly en-
coded memory representations from the
prior waking period (O’Neill et al., 2010).
Ripple-associated replay during SWS
has been considered the key mechanism
launching the consolidation of newly
acquired episodic memories (Diekelmann
and Born, 2010). Grosmark et al. report
that during ripples, cells fire more
synchronously, and this firing paradoxi-
cally increases across NonREM-REM-
NonREM sleep triplets. Moreover, the
increased synchronouswithin-ripple firing
occurred especially in those neuron
assemblies that fired with high theta and
gamma activity during interleaving REM
epochs. The data tempt us to speculate
that global processes of downscaling
occur in concert with local processes ofupscaling and shaping of memory repre-
sentations across the sleep cycle in an
interplay between ripple-associated and
theta-associated replay activity. It has
been proposed that one function of
theta-associated replaymight be to select
memories for consolidation as, depend-
ing on the phase of the theta cycle, replay
during theta potentiates or depotentiates
the activated synaptic assemblies (Poe
et al., 2000). Whatever the case, the
findings by Grosmark et al. (2012) sug-
gest that both global synaptic down-
scaling and local upscaling of specific
memory representations originate from
sequenced processes across the
NonREM-REM sleep cycle. Future re-
search might reveal that these global
and local processes are inextricably tied
to each other in jointly establishing sleep
and memory.
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Much of Parkinson’s research over the last decade has focused on cellular stress as a candidatemechanism.
In this issue of Neuron, a new study by Matta et al. (2012) addressing the biological functions of the Parkin-
son’s gene LRRK2 now identifies a presynaptic substrate, homing in on the idea that synapse loss might be
a central early aspect of neurodegeneration.Genetic mutations found in familial forms
of neurodegeneration havebeenapopular
starting point for mechanistic studies thataim to uncover the early events preceding
clinical manifestations. Common late-
onset forms of neurodegeneration, suchas Parkinson’s disease (PD) and Alz-
heimer’s disease (AD), progress slowly,
only the pathological endpoints are wellptember 20, 2012 ª2012 Elsevier Inc. 935
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Previewsdefined, and other leads to uncover these
early events are very scarce. However,
most patients suffering from PD or AD
are apparently sporadic, which makes it
hard to develop generalized hypotheses
on the causality of the disease, and it
remains uncertain to what extent we can
generalize the conclusions from studies
on rare familial mutations. The fact that
some of these familial genes are also
risk factors for sporadic cases supports
the idea that familial and sporadic forms
share a common etiology and strengthen
their validity as starting points for mecha-
nistic studies. On the other hand, animal
models that model these human muta-
tions generally do not recapitulate the
clinical features observed in patients. A
new study in this issue of Neuron indi-
cates that we may need to take smaller
steps and first go through the trouble of
understanding the biological functions of
genes associated with neurodegenera-
tion before focusing on the clinical and
pathological aspects. In doing so, neuro-
degeneration in animal models turns out
to be only one step away in the case of
the PD gene LRRK2. And as a result, the
focus of neurodegeneration research is
shifting back to the synapse.
The identification of single genetic
factors that appear to be causal for neuro-
degeneration has been rather successful,
especially for PD. Family studies have
provided a rich collection of possible
starting points for mechanistic studies
(see Cookson and Bandmann, 2010).
Mutations in the presynaptic protein
a-synuclein were the first to be identified
in familial PD. Because a-synuclein is
also the major component of the insoluble
protein aggregates or Lewy bodies in the
brain of patients, the initial focus of
many PD studies has been on synapses.
The subsequent identification of muta-
tions in Parkin, an ubiquitin E3 ligase,
together with the reported mutations of
the deubiquitinating enzyme UCH-L1 in
a single PD family, has shifted much of
the research of the past decade on the
pathological consequences of misfolded
proteins on the ubiquitin proteasome
system and how this contributes to path-
ogenesis, especially after a-synuclein
was found also to inhibit apoptosis
activation through oligomerization with
cytochrome C and to exert a protective
function by modulating S phase check-936 Neuron 75, September 20, 2012 ª2012 Epoint responses. In addition, mutations
in PD genes PINK, DJ-1, and ATP13A2
have implicated mitochondrial dysfunc-
tion in the pathogenesis of PD (see Cook-
son and Bandmann, 2010). Together, all
these findings have shifted the focus
of many PD studies to cell and mito-
chondrial stress as the central aspect of
pathogenesis.
In 2004, mutations in the leucine-rich
repeat kinase 2 (LRRK2) gene were found
to cause late-onset PD that is clinically
indistinguishable from idiopathic disease
(Paisa´n-Ruı´z et al., 2004; Zimprich et al.,
2004). LRRK2 encodes a multidomain
protein with kinase and GTPase activities
enriched in brain. The by far most com-
mon human mutation G2019S, located in
the kinase domain, has a frequency of
1% in sporadic patients and 4% in
patients with familial PD. However, patho-
genic mutations in the GTPase domain
have also been identified. Cell biological
studies, mostly using overexpression of
LRRK2, show that the most common
disease-associated mutations influence
kinase activity in vitro, accompanied by
increases in apparent neurotoxicity.
A new study addressing the physiolog-
ical roles of LRRK2 by the laboratories of
De Strooper and Verstreken (Matta et al.,
2012) has now identified EndophilinA as
a substrate of the Drosophila ortholog.
EndophilinA is a presynaptic membrane-
binding protein with curvature-generating
and -sensing properties that participates
in clathrin-dependent endocytosis of
synaptic vesicle membranes. The protein
is highly conserved in evolution, down to
yeast (Rvs167). Mammals express three
isoforms. EndophilinA forms dimers via
the N-terminal N-BAR domain, which
insert into lipids and recruit other impor-
tant endocytic proteins such as the phos-
phoinositide phosphatase synaptojanin
required for uncoating recycling vesicles
in the nerve terminal (Gallop et al., 2006;
Milosevic et al., 2011).
The study first describes the synaptic
phenotype of LRRK2-deficient fly neuro-
muscular junction, uses an elegant in vivo
genetic approach to identify EndophilinA
as a modifying gene, then demonstrates
that EndophilinA is an LRRK2 substrate
in vitro and in vivo, identifies the residue
in the protein that is phosphorylated (in
its Bin/Amphiphysin/Rvs [BAR] domain),
and finally characterizes the functionallsevier Inc.consequences of abnormal LRRK-depen-
dent EndophilinA phosphorylation at
the molecular and cellular level by ex-
pressing phosphomutants of EndophilinA
and the most common patient mutant
(G2019S) in LRRK2. These functional
consequences are quite pronounced: at
the molecular level, loss of membrane
binding and the ability of EndophilinA
to deform (tubulate) membranes are
consistent with the predicted effect of
altering the structure of the BAR domain.
At the cellular level, FM dye uptake,
a measure for endocytosis, and synaptic
transmission during intense stimulation
were reduced.
Despite almost 1,000 papers on LRRK
in PubMed, information about the identity
of its substrates is very scarce, except
for the relatively well-established auto-
phosphorylation. The in vitro and in vivo
evidence for EndophilinA obtained by
several independent approaches in the
study by Matta et al. (2012) probably
make EndophilinA the most convincing
LRRK2 substrate to date. Together, these
data provide a plausible and novel
hypothesis about why LRRK2 mutations
found in PD patients are pathogenic.
Chronic deregulation of synaptic vesicle
membrane retrieval might underlie a
slowly progressing and age-dependent
loss of synapse function and eventually
the clinical manifestations observed in
PD. Furthermore, the identification of
EndophilinA as an LRRK2 substrate also
provides intriguing links to other recent
findings. First, the ubiquitin-like domain
of another PD gene, Parkin, was re-
cently shown to bind and ubiquitinate
EndophilinA in vitro, and phosphatase
inhibitors change EndophilinA subcellular
distribution in isolated mouse nerve
terminals (Trempe et al., 2009). Hence, a
second PD gene probably regulates
EndophilinA levels and function in
synapses, and chronic disregulation of
EndophilinA function may contribute to
the pathology observed both in families
carrying mutations in Parkin or in LRRK2.
Second, inmice, loss of EndophilinA func-
tion leads to widespread neurodegenera-
tion (Milosevic et al., 2011).
Neurodegeneration in null mutant mice
for presynaptic genes is quite rare and
poorly understood. The often lethal
phenotypes prevent analysis beyond
birth. LRRK2 null mutants and also
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tion, R1441C, appear to have normal
brains and show no degeneration up to
old age (but do have a-synuclein accumu-
lations in the kidney; Tong et al., 2009,
2010), but double null mutants for its
substrate EndophilinA1/2 show numerous
vacuolar spaces containing membranes
and cell debris reminiscent of spongiform
neurodegeneration already soon after
birth (Milosevic et al., 2011). It is not
clear how well these features resemble
degeneration observed in PD patients.
Of course, EndophilinA function is com-
pletely lost in the null mutant mouse and
degeneration is evident soon after birth,
while LRRK2 dysregulation would at
most confer a very partial loss of Endophi-
linA function. Furthermore, degeneration
in the null mutant is not restricted to
the dopamine system, and progression
cannot be followed because the Endophi-
linA mutants die within weeks, but it
seems plausible that more subtle and
slowly developing forms of this type of
neurodegeneration eventually contribute
to neuronal loss observed in PD patients.
Why EndophilinA loss-of-function mice
show degeneration is an intriguing open
question. It seems unlikely that this
degeneration is simply the result of a
defective synaptic vesicle cycle. First,
synaptic transmission is reduced but
certainly not blocked in EndophilinA
mutant neurons (Milosevic et al., 2011)
and, second, other mutants with stronger
defects show no sign of degeneration
until birth, such as the syb2/VAMP2
or synaptotagmin1 or 2 null mutants.
Such mutants typically show severe
defects in synaptic transmission and
paralysis, but no brain degeneration, and
neurons from the prenatal brains of these
mutants can be maintained in culture for
weeks without signs of neuronal loss. A
mutant that is completely devoid of
synaptic transmission, and also of spon-
taneous events, still shows no sign of
degeneration at birth and neurons can
be maintained in culture (Varoqueaux
et al., 2002). Hence, a defective synaptic
vesicle cycle seems an unlikely explana-
tion for the observed neurodegeneration
in EndophilinA loss-of-function mice.
Only a limited number of loss-of-function
models for presynaptic proteins show
neurodegeneration like EndophilinA
mice. Among the few examples are nullmutants for Munc18-1, cysteine string
protein (CSP), and SNAP25 (the latter
only in cultured neurons). It is difficult to
assess whether thesemodels have some-
thing in common and what that might be.
At least the latter two seem connected
because CSP is a SNAP25 chaperone
and degeneration in the CSP null mutant
mice is due to impaired SNAP25 function
(Chandra et al., 2005). Interestingly,
CSP lethality and neurodegeneration are
rescued by overexpression of the familial
PD gene a-synuclein (Sharma et al.,
2012). Another question that remains
open is why dopaminergic neurons are
preferentially affected in PD. The distribu-
tion of neither LRRK2 nor EndophilinA
provides clues to this issue.
Interestingly, the study of Matta et al.
(2012) shows that both an LRRK2 patient
mutation, generally accepted as a gain of
function, as well as the loss of the kinase
by genetic deletion produce a similar
defect on synaptic function. In line with
this, transfection studies in human heter-
ologous cells show that both kinase-
activating mutations and kinase-dead
mutations have similar (toxic) effects (see
Cookson and Bandmann, 2010). Appar-
ently, the balance between phosphory-
lated and nonphosphorylated substrates
is delicate and needs to be maintained
within a specific window. In addition, an
active phosphorylation-dephosphoryla-
tion cycle seems to be required, as both
the phosphomimicking and nonphos-
phorylatable versions of EndophilinA pro-
duce similar synaptic defects.
It remains to be determined how
different human mutations in LRRK2
should be interpreted in the light of the
current findings. Sporadic PD is a late-
onset disease and familial cases carrying
LRRK2 mutations are typically also late
onset. Despite the presence of this
genetic defect from birth onward, clinical
symptoms take decades to become clini-
cally evident. In addition, the identified
human LRRK2 mutations show a clearly
reduced penetrance. For example, the
risk of PD for a person with an LRRK2
G2019S mutation that was investigated
by Matta et al. (2012) increases with age.
At the age of 59 it is 28%, at age 69 it
is 51%, and at the age of 79 years it is
74% (Healy et al., 2008). One can there-
fore expect that the biological functions
affected by the mutation are not essentialNeuron 75, Seand are likely to have only a very mild
effect on important biological processes
like synaptic transmission. The relatively
mild effects even of complete deletion of
LRRK expression in the study by Matta
et al. (2012) are in line with this.
Still, it is quite remarkable that despite
the intense interest for LRRK2 and the
availability of mutant mice and cell
models for this kinase, the endocytosis
defects have not been observed before,
except for some scattered observations
(Shin et al., 2008; Piccoli et al., 2011). In
addition to the fact that the overall effects
on synaptic transmission are mild, a
second reason might be that the primary
goal of many researchers creating and
studying animal models for neurodegen-
eration has been to recapitulate the
clinical and pathological findings of the
human disease. Unfortunately, not many
such models exist despite a wide range
of models generated in different species.
One could therefore wonder whether it
is even realistic to have these expecta-
tions. Maybe the differences between
humans and animal species in, for exam-
ple, brain organization and life span are
simply too large? However, animal
models do exist that each mimic different
aspects of the disease such as the
pathological aggregation of misfolded
proteins like a-synuclein. Often this
requires the construction of complex
models like double or triple transgenics
to show clear phenotypes, while the
actual biological mechanisms resulting
from the pathogenic mutations have
received far less attention. Hence, consid-
ering the expected effect size of the path-
ogenic mutations, the question arises
whether the field has studied in enough
molecular detail the existing models and
especially those models that mimic the
human mutations or even the human
genomic locus without overexpression or
other additional manipulations.REFERENCES
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Hippocampal dentate granule cell abnormalities are thought to play a causative role in temporal lobe
epilepsy, but their precise contribution has not been dissociated from coexisting pathological changes. In
this issue of Neuron, Pun et al. (2012) show, for the first time, that inducing proexcitatory changes in a subset
of DGCs in isolation is sufficient to cause epilepsy in a rodent.The epilepsies are a diverse group of
disorders in which seizures are the
defining manifestation. Seizure initiation
and spread in temporal lobe epilepsy
(TLE), one of the most common and
intractable epilepsies in adolescents and
adults, is thought to involve medial
temporal structures, such as the hippo-
campus, parahippocampal regions, and
amygdala. These regions often display
distinct histopathology, the hallmark of
which is Ammon’s horn sclerosis (AHS).
AHS is characterized by pronounced
pyramidal and hilar neuronal cell death,
astrogliosis, and proexcitatory reorgani-
zation of dentate granule cells (DGCs).
The dentate gyrus typically acts as a
‘‘gate’’ for excitatory input to the hippo-
campus, and accumulating evidence
suggests that DGC reorganization in ex-
perimental TLE breaks down this gating
function (Pathak et al., 2007). As a result,
DGC structural remodeling is hypothe-
sized to be pro-epileptogenic.Under normal conditions, DGCs re-
ceive strong feedforward and feedback
inhibition and do not synapse onto one
another. Their somas reside in the granule
cell layer and they extend apical dendrites
into themolecular layer and axons into the
hilus and statum lucidum of area CA3
(Figure 1A). DGCs synapse onto mossy
cells and inhibitory interneurons in the
hilus, and onto pyramidal cells in CA3. In
human and experimental TLE, DGC
somas may enlarge, some are found
ectopically in the hilus and molecular
layer, a subset display basal dendrites
extending abnormally into the hilus, and
DGC axon collaterals sprout into the inner
molecular layer (Figure 1B), a process
known as mossy fiber sprouting. These
changes are associated with increased
excitatory input and aberrant DGC inter-
connectivity (Parent, 2007) and are
believed to promote hypersynchronous
spread of excitation through the hippo-
campus. Recent work also implicatesaltered adult DGC neurogenesis in exper-
imental TLE (Jessberger et al., 2007; Kron
et al., 2010; Parent et al., 2006; Walter
et al., 2007). DGCs that develop during
or after an epileptogenic insult appear to
be most susceptible to aberrant integra-
tion that may cause hyperexcitability
(Jessberger et al., 2007; Kron et al.,
2010; Walter et al., 2007), and suppress-
ing adult neurogenesis variably attenu-
ates the seizure phenotype in rodent
models of TLE (Jung et al., 2004). In
contrast, normally integrated, adult-
generated DGCs may play an anti-epilep-
togenic role (Jakubs et al., 2006). To
date, it has been difficult to distinguish
between changes that are pathological
and those that are not functionally rele-
vant or perhaps even homeostatic in TLE.
In this issue, Pun et al. (2012) induce
abnormal integration of DGCs in relative
isolation to determine whether this is
sufficient to cause epilepsy. To accom-
plish this, they conditionally ablate the
